HOECHST/BIOVAIL ONCE-DAILY DILTIAZEM NDA APPROVAL DELAYED UNTIL MAY 1996
Executive Summary
HOECHST/BIOVAIL ONCE-DAILY DILTIAZEM NDA APPROVAL DELAYED UNTIL MAY 1996 by Marion Merrell Dow's manipulation of 505(b) regulations, Biovail alleges in an antitrust suit filed Oct. 19 in San Juan, Puerto Rico federal court. Biovail notes that because MMD filed a patent infringement suit, Hoechst's NDA cannot be approved by FDA until 30 months after MMD's receipt of the 505(b) notice, or May 1996, unless the federal court orders otherwise. MMD's patent suit is part of a "scheme to manipulate the administrative regulations to their benefit...impairing [Biovail's] ability to compete in the sustained-release diltiazem market," Biovail charges.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: